News

Are you interested in a Ph.D. position linking Pharmetheus with two leading centers, Sanofi and the School of Pharmacy at Aix Marseille University? Join us in advancing PBPK modeling of subcutaneously administered

Will you attend Page 2022 and would benefit from additional insights on a) leveraging in vitro data or b) interpreting covariate effects in models? We have a few last spots left in

It is our pleasure to introduce Anna Mc Laughlin, Associate Consultant, who recently joined Pharmetheus. Anna’s experience includes pharmacometrics and model-informed precision dosing in oncology and immuno-oncology, especially in cellular therapies, oral

In 2021, the FDA granted an accelerated approval to tepotinib for metastatic non-small cell lung cancer. Earlier on, tepotinib had been approved for the treatment of advanced non-small cell lung cancer by

Pharmetheus is delighted to count Birgit Köster Hoffman among its new Board members. Birgit, an experienced international CEO and CFO, has developed an expertise as a Non Executive Board Professional in highly

Warmly welcoming Georgina Nilsson, as a new Project Coordinator to Pharmetheus. Georgina brings experience working in international teams, within marketing and project. See Georgina’s bio here.

Pharmetheus, a proud sponsor of the Quantitative Systems Pharmacology Conference – QSPC 2022,  and our team on site Eric Salgado, Erik Sjögren, Julie Janssen, Marylore Chenel, Per Lundström, Peter Milligan, would like

How to successfully generate an alternative approach to a thorough QT Study? Scientists from Galapagos, Servier and Pharmetheus have in collaboration published a tutorial describing a path to create a feasible alternative

We wish a warm welcome to Magnus Forsbrand, new Board Member at Pharmetheus.  Magnus has served on more than ten Board of Directors and been CEO in four companies. In his own